Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM, Rutkowski P, Dutriaux C, Hofman-Wellenhof R, Dziewulski P, Marples M, Grange F, Lok C, Pennachioli E, Robert C, van Akkooi ACJ, Bastholt L, Minisini A, Marshall E, Salès F, Grob JJ, Bechter O, Schadendorf D, Marreaud S, Kicinski M, Suciu S, Testori AAE. Eggermont AMM, et al. Among authors: lok c. Eur J Cancer. 2020 Jul;133:94-103. doi: 10.1016/j.ejca.2020.04.015. Epub 2020 May 26. Eur J Cancer. 2020. PMID: 32470710 Clinical Trial.
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ. Grob JJ, et al. Among authors: lok c. Lancet. 1998 Jun 27;351(9120):1905-10. doi: 10.1016/s0140-6736(97)12445-x. Lancet. 1998. PMID: 9654256 Clinical Trial.
Melanoma and tumor thickness: challenges of early diagnosis.
Richard MA, Grob JJ, Avril MF, Delaunay M, Thirion X, Wolkenstein P, Souteyrand P, Dreno B, Bonerandi JJ, Dalac S, Machet L, Guillaume JC, Chevrant-Breton J, Vilmer C, Aubin F, Guillot B, Beylot-Barry M, Lok C, Raison-Peyron N, Chemaly P. Richard MA, et al. Among authors: lok c. Arch Dermatol. 1999 Mar;135(3):269-74. doi: 10.1001/archderm.135.3.269. Arch Dermatol. 1999. PMID: 10086447
Delays in diagnosis and melanoma prognosis (I): the role of patients.
Richard MA, Grob JJ, Avril MF, Delaunay M, Gouvernet J, Wolkenstein P, Souteyrand P, Dreno B, Bonerandi JJ, Dalac S, Machet L, Guillaume JC, Chevrant-Breton J, Vilmer C, Aubin F, Guillot B, Beylot-Barry M, Lok C, Raison-Peyron N, Chemaly P. Richard MA, et al. Among authors: lok c. Int J Cancer. 2000 May 20;89(3):271-9. Int J Cancer. 2000. PMID: 10861504 Free article.
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study.
Jouary T, Leyral C, Dreno B, Doussau A, Sassolas B, Beylot-Barry M, Renaud-Vilmer C, Guillot B, Bernard P, Lok C, Bedane C, Cambazard F, Misery L, Estève E, Dalac S, Machet L, Grange F, Young P, Granel-Brocard F, Truchetet F, Vergier B, Delaunay MM, Grob JJ; Groupe de Cancérologie Cutanée of the Société Française de Dermatologie. Jouary T, et al. Among authors: lok c. Ann Oncol. 2012 Apr;23(4):1074-80. doi: 10.1093/annonc/mdr318. Epub 2011 Jul 12. Ann Oncol. 2012. PMID: 21750118 Free article. Clinical Trial.
Malignant melanoma and granulomatosis.
Robert C, Schoenlaub P, Avril MF, Lok C, Grosshans E, Valeyre D, Bourgeois C, Pinquier L, Dubertret L, Guillaume JC. Robert C, et al. Among authors: lok c. Br J Dermatol. 1997 Nov;137(5):787-92. Br J Dermatol. 1997. PMID: 9415243
Delays in diagnosis and melanoma prognosis (II): the role of doctors.
Richard MA, Grob JJ, Avril MF, Delaunay M, Gouvernet J, Wolkenstein P, Souteyrand P, Dreno B, Bonerandi JJ, Dalac S, Machet L, Guillaume JC, Chevrant-Breton J, Vilmer C, Aubin F, Guillot B, Beylot-Barry M, Lok C, Raison-Peyron N, Chemaly P. Richard MA, et al. Among authors: lok c. Int J Cancer. 2000 May 20;89(3):280-5. doi: 10.1002/1097-0215(20000520)89:3<280::aid-ijc11>3.0.co;2-2. Int J Cancer. 2000. PMID: 10861505 Free article.
The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study.
Grob JJ, Richard MA, Gouvernet J, Avril MF, Delaunay M, Wolkenstein P, Souteyrand P, Bonerandi JJ, Machet L, Guillaume JC, Chevrant-Breton J, Vilmer C, Aubin F, Guillot B, Beylot-Barry M, Lok C, Raison-Peyron N, Chemaly P. Grob JJ, et al. Among authors: lok c. Int J Cancer. 2002 Nov 1;102(1):34-8. doi: 10.1002/ijc.10660. Int J Cancer. 2002. PMID: 12353231 Free article.
Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.
Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C. Jouary T, et al. Among authors: lok c. Acta Derm Venereol. 2015 Sep;95(7):835-40. doi: 10.2340/00015555-2099. Acta Derm Venereol. 2015. PMID: 25784178 Free article.
723 results